Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

PEMMARAJU, NAVEEN

One or more keywords matched the following items that are connected to PEMMARAJU, NAVEEN

Item Type	Name
Concept	Receptors, Interleukin-7
Concept	Interleukin-3 Receptor alpha Subunit
Concept	Receptors, Interleukin-3
Concept	Interleukin-3
Academic Article	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Academic Article	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
Academic Article	Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.
Academic Article	Treatment advances in blastic plasmacytoid dendritic cell neoplasm.
Academic Article	Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.
Academic Article	Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
Academic Article	Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Academic Article	Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall.
Academic Article	Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
Academic Article	CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies.
Academic Article	Targeting CD123 in BPDCN: an emerging field.
Academic Article	Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Academic Article	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Academic Article	Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Academic Article	Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Academic Article	First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia.
Academic Article	North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Academic Article	CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
Academic Article	Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Academic Article	Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Academic Article	Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Academic Article	Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Academic Article	CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.

Search Criteria

Interleukin 3